<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
<item congress="115" measure-type="hr" measure-number="4374" measure-id="id115hr4374" originChamber="HOUSE" orig-publish-date="2017-11-13" update-date="2018-02-09">
<title>To amend the Federal Food, Drug, and Cosmetic Act to authorize additional emergency uses for medical products to reduce deaths and severity of injuries caused by agents of war, and for other purposes.</title>
<summary summary-id="id115hr4374v49" currentChamber="BOTH" update-date="2018-02-09">
<action-date>2017-12-12</action-date>
<action-desc>Public Law</action-desc>
<summary-text><![CDATA[<p>(This measure has not been amended since it was introduced. The expanded summary of the House passed version is repeated here.)</p> <p>(Sec. 1) This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA)&nbsp;to authorize&nbsp;the emergency use of an otherwise unapproved&nbsp;medical product if the Department of Defense (DOD)&nbsp;determines that there is a military emergency involving an agent that may cause imminently life-threatening and specific risk to U.S. forces. If a military emergency is determined to exist, the bill allows DOD to request that the FDA&nbsp;expedite certain procedures for approving medical&nbsp;products that would be reasonably likely to diagnose, prevent, treat, or mitigate such risk.&nbsp;The FDA&nbsp;must take specified&nbsp;actions to facilitate such a request by DOD.</p> <p>The bill repeals provisions of the National Defense Authorization Act for Fiscal Year 2018 that allow DOD, rather than the FDA,&nbsp;to authorize the emergency use of an unapproved product under similar circumstances.</p> <p>Unless DOD determines&nbsp;such meetings to be unnecessary, the FDA shall meet with&nbsp;DOD:&nbsp;(1) semi-annually to conduct a full review of relevant medical products in the DOD portfolio; and (2) quarterly to discuss the development status of regenerative medicine advanced therapy, blood, and vaccine medical products and projects that DOD prioritizes. </p>]]></summary-text>
</summary>
<summary summary-id="id115hr4374v82" currentChamber="SENATE" update-date="2018-02-09">
<action-date>2017-11-16</action-date>
<action-desc>Passed Senate without amendment</action-desc>
<summary-text><![CDATA[<p>(This measure has not been amended since it was introduced. The expanded summary of the House passed version is repeated here.)</p> <p>(Sec. 1) This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA)&nbsp;to authorize&nbsp;the emergency use of an otherwise unapproved&nbsp;medical product if the Department of Defense (DOD)&nbsp;determines that there is a military emergency involving an agent that may cause imminently life-threatening and specific risk to U.S. forces. If a military emergency is determined to exist, the bill allows DOD to request that the FDA&nbsp;expedite certain procedures for approving medical&nbsp;products that would be reasonably likely to diagnose, prevent, treat, or mitigate such risk.&nbsp;The FDA&nbsp;must take specified&nbsp;actions to facilitate such a request by DOD.</p> <p>The bill repeals provisions of the National Defense Authorization Act for Fiscal Year 2018 that allow DOD, rather than the FDA,&nbsp;to authorize the emergency use of an unapproved product under similar circumstances.</p> <p>Unless DOD determines&nbsp;such meetings to be unnecessary, the FDA shall meet with&nbsp;DOD:&nbsp;(1) semi-annually to conduct a full review of relevant medical products in the DOD portfolio; and (2) quarterly to discuss the development status of regenerative medicine advanced therapy, blood, and vaccine medical products and projects that DOD prioritizes. </p>]]></summary-text>
</summary>
<summary summary-id="id115hr4374v81" currentChamber="HOUSE" update-date="2018-02-09">
<action-date>2017-11-15</action-date>
<action-desc>Passed House without amendment</action-desc>
<summary-text><![CDATA[<p>(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)</p> <p>(Sec. 1) This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA)&nbsp;to authorize&nbsp;the emergency use of an otherwise unapproved&nbsp;medical product if the Department of Defense (DOD)&nbsp;determines that there is a military emergency involving an agent that may cause imminently life-threatening and specific risk to U.S. forces. If a military emergency is determined to exist, the bill allows DOD to request that the FDA&nbsp;expedite certain procedures for approving medical&nbsp;products that would be reasonably likely to diagnose, prevent, treat, or mitigate such risk.&nbsp;The FDA&nbsp;must take specified&nbsp;actions to facilitate such a request by DOD.</p> <p>The bill repeals provisions of the National Defense Authorization Act for Fiscal Year 2018 that allow DOD, rather than the FDA,&nbsp;to authorize the emergency use of an unapproved product under similar circumstances.</p> <p>Unless DOD determines&nbsp;such meetings to be unnecessary, the FDA shall meet with&nbsp;DOD:&nbsp;(1) semi-annually to conduct a full review of relevant medical products in the DOD portfolio; and (2) quarterly to discuss the development status of regenerative medicine advanced therapy, blood, and vaccine medical products and projects that DOD prioritizes. </p>]]></summary-text>
</summary>
<summary summary-id="id115hr4374v00" currentChamber="HOUSE" update-date="2018-02-06">
<action-date>2017-11-13</action-date>
<action-desc>Introduced in House</action-desc>
<summary-text><![CDATA[<p>This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA)&nbsp;to authorize&nbsp;the emergency use of an otherwise unapproved&nbsp;medical product if the Department of Defense (DOD)&nbsp;determines that there is a military emergency involving an agent that may cause imminently life-threatening and specific risk to U.S. forces. If a military emergency is determined to exist, the bill allows DOD to request that the FDA&nbsp;expedite certain procedures for approving medical&nbsp;products that would be reasonably likely to diagnose, prevent, treat, or mitigate such risk.&nbsp;The FDA&nbsp;must take specified&nbsp;actions to facilitate such a request by DOD.</p> <p>The bill repeals provisions of the National Defense Authorization Act for Fiscal Year 2018 that allow DOD, rather than the FDA,&nbsp;to authorize the emergency use of an unapproved product under similar circumstances.</p> <p>Unless DOD determines&nbsp;such meetings to be unnecessary, the FDA shall meet with&nbsp;DOD:&nbsp;(1) semi-annually to conduct a full review of relevant medical products in the DOD portfolio; and (2) quarterly to discuss the development status of regenerative medicine advanced therapy, blood, and vaccine medical products and projects that DOD prioritizes. </p>]]></summary-text>
</summary>
</item>
<dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
<dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
<dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
</dublinCore>
</BillSummaries>
